Sanofi Pasteur MSD GmbH

Sanofi Pasteur MSD Welcomes European Initiatives to set Vaccination as Standard of Prevention in Seniors

Lyon, France (ots/PRNewswire) - Results of review-based evidence on the public healthvalue of vaccination for seniors in Europe presented at WAidid congress

The first Biennial Congress of the World Association for Infectious Diseases and Immunological Disorders (WAidid), has been held in Milan on February 18-20, 2016.

Two review-based posters* co-authored by a group of European experts and Sanofi Pasteur MSD demonstrated the striking remaining burden of vaccine-preventable diseases in seniors in Europe due to suboptimal vaccine coverage rates (VCR) and heterogeneous vaccination recommendations for seniors across Europe.

"With vaccine-preventable diseases now well controlled in the Paediatric population, a far greater number of cases of some vaccine-preventable diseases occur in seniors, notably since the size of this population keeps increasing," noted Dr Susanna Esposito. "It is important to understand that vaccines are not just for children and that vaccination should also be regarded as a key component of routine prevention to preserve the health of our seniors," she concluded.

With an ageing European population, vaccination is a critical component of preventive strategies to reduce burden of illness and save lives. It aims also at preventing severe complications and their adverse impact on age-related functional decline that could lead to loss of autonomy.

Several vaccinations are recommended across Europe for seniors, mostly in the population aged 65 years and over to protect them against diseases such as influenza, pneumococcal diseases, pertussis, zoster considering their higher vulnerability due to the age-related natural decrease of the immune system (the so-called "immunosenescence").

"In seniors, some infectious diseases such as influenza, pneumococcal diseases or zoster can have a worst outcome compared to younger population, leading in some cases to a cascade of events and to a decline in their functional status, stated Dr Gaetan Gavazzi." The occurrence of these diseases in seniors can be the start of loss of autonomy, whereas it could be averted thanks to vaccination," he added.

When compared with high childhood VCR (more than 90% of one-year-old children received the nationally recommended diphtheria, tetanus and pertussis (DTaP) and measles vaccinations), the VCR in seniors are far lower in the same European countries. For example, despite flu VCR, official target of 75% recommended by WHO and the EU council, only two countries managed to reach it or nearly (The Netherlands and the United Kingdom) to date. In 2012-13, influenza VCR in seniors varied from 1% to 77% (the median was 45%) in 24 European countries[1] and is globally declining throughout Europe in recent years.

Exclusively dedicated to vaccines in Europe, Sanofi Pasteur MSD is a committed Public Health partner, fully focused on European citizens health and sustainability of the healthcare systems. This review demonstrates that vaccines have a key role to play in healthy ageing strategies. In addition to the significant reduction in health spending closely related to health-related quality of daily life, it also emphasises the need for better immunisation programmes for seniors in Europe to ensure the same level of successful outcomes as observed for childhood vaccination.

Key facts from: "REVIEW OF EPIDEMIOLOGICAL AND MORBIDITY-MORTALITY 
DATA OF VACCINE-PREVENTABLE DISEASES IN SENIORS IN EUROPE".  
Influenza: It is estimated that about 38,500 deaths occur each year 
in the EU/EEA countries[2] with 90% in seniors[3]. In France, during 
the 2014-15 flu season, about 30,000 cases were admitted to intensive
care units with influenza resulting in 3133 hospitalizations (47% in 
65+) and  mortality exceeded average mortality by 18,300 individuals 
(90% in 65+). This excess was due to influenza and other winter 
related factors[4] . Same trend in most EU countries[4].  
Pneumococcal diseases: 20,785 confirmed cases of invasive 
pneumococcal disease were reported by 27 EU/EEA countries in 2012, 
predominantly in seniors[5].  Zoster: consequence of the reactivation
of the varicella zoster virus which remains latent following 
varicella, zoster represents more than 1.7 million new cases all ages
each year in Europe[6]. The risk increases with age[6]. More than 40%
of those over 60 years who have had herpes zoster suffer from 
post-herpetic neuralgia[7].  Diphtheria: in 2012, 27 cases of 
diphtheria reported by 8 EU/EEA countries, the majority being in 
seniors[8].  Tetanus: In 2012, 123 cases reported, 80% in seniors[8].
Pertussis: in 2012, 42 525 cases reported by 28 EU/EEA countries[8].
The overall total case rate was twice as high as in previous 
years[8]. Incidence is increasing in adolescents and adults and gives
reasons for concern of transmission to infants[8].  Polio: no case in
any of the 29 reporting EU/EEA countries in 2012[8]. 

About WAidid Congress:

The World Association for Infectious Diseases and Immunological Disorders (WAidid) was founded in July 2014 to advance the scientific research in the field of infectious diseases and immunology and to disseminate information on the related pathologies both at National and International level.

About Sanofi Pasteur MSD http://www.spmsd.com

Sanofi Pasteur MSD is a European joint venture formed between Sanofi Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside the United States and Canada). Combining innovation and expertise, Sanofi Pasteur MSD is the only European pharmaceutical company dedicated exclusively to the development of vaccines. Sanofi Pasteur MSD makes use of the combined expertise resulting from Sanofi Pasteur and Merck's research to focus on the development of new vaccines in Europe in order to produce the most effective, most acceptable and better tolerated vaccines.

* Vaccination of seniors in Europe : The state of play of recommendations and coverage rates compared with childhood vaccination :

Authors : S. Esposito1, E. Franco2, G. Gavazzi3, A. Gil de Miguel4, 
R. Hardt5, G. Kassianos6, M.C. Levant7, J.A. López Trigo8   
-Pediatric Highly Intensive Care Unit, Department of Pathophysiology 
& Transplantation, Università degli Studi di Milano, Milan, Italy   -
Dipartimento di Biomedicina e Prevenzione - Università Degli Studi di
Roma Tor Vergata, Roma, Italy   - Université de Grenoble-Alpes et 
GREPI, clinique universitaire de médecine gériatrique, CHU de 
Grenoble, la tronche, France   - Catedrático de Medicina Preventiva y
Salud Pública, Universidad Rey Juan Carlos, Madrid, Spain   - 
Department of Geriatric Medicine, St. Hildegardis-Hospital, Mainz, 
Germany   - Royal College of General Practitioners Immunisation Lead,
President British Global & Travel Health Association and General 
Practitioner, Bracknell, UK   - Medical Affairs, Sanofi Pasteur MSD, 
Lyon, France   - Spanish Society of Geriatrics and Gerontology 
President, Committee member vaccines of SEGG, Malaga, Spain 

References

[1] European Center for Disease Prevention and Control. Seasonal influenza vaccination in Europe. Overview of vaccination recommendations and coverage rates in the EU Member States for the 2012-13 influenza season. Jan 2015. Available at http://ecdc.europa.eu/en/press/news/_layouts/forms/News_DispForm.aspx?List=8db7286c-fe2d-476c-9133-18ff4cb1b568&ID=1154 (Accessed February 10, 2016).

[2]European Centers for Disease Prevention and Control. Scientific advice: revised estimates of deaths associated with seasonal influenza in the US. Oct 4, 2010. Available at: http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=394 (Accessed March 23, 2015).

[3]European Centers for Disease Prevention and Control. Mortality from influenza. Available at:

http://www.ecdc.europa.eu/en/healthtopics/H1N1/basic_facts/Pages/mortality_from_influenza.aspx (Accessed March 23, 2015).

[4] InVS. Grippe Bilan de la saison 2014-2015.May 22, 2015. Available at: http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Grippe/Grippe-generalites/Donnees-de-surveillance

[5]European Centre for Disease Prevention and Control. Annual epidemiological report 2014 - Vaccine-preventable diseases - invasive bacterial diseases. Stockholm: ECDC; 2015.

[6]Pinchinat S et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infectious Diseases. 2013; 13:170

[7]Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; 356:1338-134.

[8]European Centre for Disease Prevention and Control. Annual epidemiological report 2014 vaccine-preventable diseases. Stockholm: ECDC; 2014.

Contact:

Sanofi Pasteur MSD
Sylvia Martin-Jarrand
Tel : +33-4-37-28-40-55
smartin-jarrand@spmsd.com
Sanofi Pasteur MSD
Loïc Frerejouand
lfrerejouand@spmsd.com
Original-Content von: Sanofi Pasteur MSD GmbH, übermittelt durch news aktuell

Das könnte Sie auch interessieren: